Skip to main content

Table 1 Patient characteristics

From: Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

  Patients (n = 120)
Age at initial diagnosis (years)
  < 30 1 (00.0)
 30–39 1 (00.0)
 40–49 4 (03.3)
 50–59 28 (23.3)
 60–69 43 (35.8)
 70–79 34 (28.3)
  ≥ 80 9 (07.5)
 Mean 65
Sex
 Female 61 (50.8)
 Male 59 (49.2)
Race
 White 96 (80.0)
 Other 17 (14.2)
 Unknown 7 (05.8)
Vital status at last follow up
 Alive 60 (50.0)
 Dead 60 (50.0)
Checkpoint inhibitor
 atezolizumab 2 (01.7)
 ipilimumab + nivolumab 2 (01.7)
 nivolumab 79 (65.8)
 pembrolizumab 37 (30.8)